BridgeBio Pharma (NASDAQ:BBIO) Q3 2025 Revenue Beat Overshadowed by Widened Loss

BridgeBio Pharma Reports Q3 2025 Earnings: Revenue Beat Overshadowed by Widened Loss

BRIDGEBIO PHARMA INC (NASDAQ:BBIO) announced its third quarter 2025 financial results, delivering a significant revenue beat driven by its commercial product Attruby while reporting a larger-than-expected quarterly loss. The biopharmaceutical company's earnings release revealed both strong commercial momentum and substantial ongoing investments in its expanding pipeline.

Financial Performance Versus Estimates

The company reported total revenue of $120.7 million for the quarter ended September 30, 2025, substantially exceeding analyst estimates of $108.5 million. This represents a dramatic increase from the $2.7 million reported in the same quarter last year, marking the company's transition toward a commercial-stage organization.

Key financial metrics from the quarter include:

• Revenue Performance:

  • Reported Revenue: $120.7 million
  • Analyst Estimate: $108.5 million
  • Beat: $12.2 million (11.2% above estimates)

• Earnings Per Share:

  • Reported EPS: -$0.95
  • Analyst Estimate: -$0.89
  • Miss: -$0.06 per share

• Revenue Composition:

  • U.S. Attruby net product revenue: $108.1 million
  • License and services revenue: $8.3 million
  • Royalty revenue: $4.3 million

The revenue beat was primarily driven by the successful commercial launch of Attruby, which generated $108.1 million in net product revenue during the quarter. However, the company's net loss attributable to common stockholders widened to $182.7 million, compared to $162.0 million in the prior year period, reflecting increased commercial and research investments.

Market Reaction and Investor Sentiment

Following the earnings release, BridgeBio shares declined approximately 5.9% in after-hours trading. This negative price action suggests investor focus may be centered on the wider-than-expected loss despite the strong revenue performance. The market reaction indicates concerns about the company's ongoing cash burn and path to profitability, even as its flagship product demonstrates significant commercial traction.

The company ended the quarter with $645.9 million in cash, cash equivalents, and marketable securities, providing substantial runway to continue commercializing Attruby and advancing its late-stage pipeline.

Commercial Progress and Pipeline Updates

Beyond the financial results, BridgeBio provided substantial updates on its commercial performance and clinical development pipeline:

• Attruby Commercialization: The company reported 5,259 unique patient prescriptions written by 1,355 unique prescribers as of October 25, 2025, demonstrating accelerating adoption since FDA approval in November 2024.

• Pipeline Milestones: BridgeBio announced positive topline results from multiple late-stage studies:

  • BBP-418 for LGMD2I/R9 showed statistically significant improvements in key biomarkers and functional measures
  • Encaleret for ADH1 met all primary and key secondary endpoints with 76% of participants achieving target calcium ranges
  • The company plans to submit New Drug Applications for both programs in the first half of 2026

• Future Catalysts: Topline results from the PROPEL 3 study of infigratinib for achondroplasia are expected in early 2026, representing another potential near-term commercial opportunity.

Operational Expenses and Investment Strategy

Operating costs and expenses increased to $265.9 million for the quarter, up from $194.5 million in the prior year period. This increase was primarily driven by investments in commercial activities for Attruby and advancement of the company's pipeline programs. Research and development expenses decreased slightly to $112.9 million, reflecting strategic reprioritization of development programs.

Forward Outlook and Analyst Expectations

While the earnings release did not provide specific financial guidance, analyst estimates for the full year 2025 project sales of approximately $477.4 million. For the fourth quarter of 2025, analysts are forecasting revenue of approximately $128.2 million. The company's strong commercial performance in Q3 positions it well to meet or exceed these expectations, though the lack of formal guidance may contribute to investor uncertainty.

For more detailed earnings analysis and future estimates, investors can review additional data on the BridgeBio earnings estimates page.

Disclaimer: This article provides financial analysis based on publicly available information and is not intended as investment advice. Investors should conduct their own research and consult with financial advisors before making investment decisions.